A carregar...
The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
Aberrant receptor kinase signalling and tumour neovascularization are hallmarks of medulloblastoma development and are both considered valuable therapeutic targets. In addition to VEGFR1/2, expression of PDGFR α/β in particular has been documented as characteristic of metastatic disease correlating...
Na minha lista:
| Publicado no: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5867109/ https://ncbi.nlm.nih.gov/pubmed/29377550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13489 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|